Paran Yael, Mashav Noa, Henis Oren, Swartzon Michael, Arbel Yaron, Justo Dan
Department of Internal Medicine, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Anadolu Kardiyol Derg. 2008 Aug;8(4):260-5.
We studied all English-written peer-reviewed reports on drug-induced torsades de pointes (TdP) in patients aged 80 years or more in order to characterize the clinical circumstances leading to this serious complication.
Our literature search yielded 24 reports on 25 patients aged 80-95 years with drug-induced TdP. We systematically reviewed each report and recorded the non-modifiable risk factors for drug-induced TdP (i.e., female sex and structural heart disease) as well as preventable clinical circumstances, which might have been associated with drug-induced TdP.
The most prevalent risk factors for drug-induced TdP were non-modifiable risk factors: 22 (88%) patients were female patients and 19 (76%) patients had structural heart disease. Overall, 16 (64%) patients were female patients with structural heart disease. The literature did not report any elderly male patients without structural heart disease. Among the preventable clinical circumstances, which might have been associated with drug-induced TdP, the most prevalent were: administrating QT prolonging agents despite long QT interval (n=11; 44%) and co-administration of two or more QT prolonging agents (n=9; 36%). The most prevalent QT prolonging agents found to trigger TdP were macrolides and quinolones (n=9; 36%). All but three patients had at least one or more preventable clinical circumstances, which might have been associated with drug-induced TdP.
Physicians should be more aware of the risk for drug-induced TdP in patients aged 80 years or more while administrating QT prolonging agents despite long QT interval and co- administrating two or more QT prolonging agents, specifically in elderly female patients with structural heart disease.
我们研究了所有关于80岁及以上患者药物性尖端扭转型室性心动过速(TdP)的英文同行评审报告,以明确导致这一严重并发症的临床情况。
我们的文献检索得到了24篇关于25例年龄在80 - 95岁药物性TdP患者的报告。我们系统地回顾了每篇报告,并记录了药物性TdP的不可改变风险因素(即女性和结构性心脏病)以及可能与药物性TdP相关的可预防临床情况。
药物性TdP最常见的风险因素是不可改变的风险因素:22例(88%)患者为女性,19例(76%)患者患有结构性心脏病。总体而言,16例(64%)患者为患有结构性心脏病的女性。文献中未报告任何无结构性心脏病的老年男性患者。在可能与药物性TdP相关的可预防临床情况中,最常见的是:尽管QT间期延长仍使用延长QT间期的药物(n = 11;44%)以及联合使用两种或更多种延长QT间期的药物(n = 9;36%)。发现引发TdP最常见的延长QT间期药物是大环内酯类和喹诺酮类(n = 9;36%)。除3例患者外,所有患者都至少有一个或多个可能与药物性TdP相关的可预防临床情况。
医生在使用延长QT间期的药物时,尤其是在患有结构性心脏病的老年女性患者中,尽管QT间期延长仍使用延长QT间期的药物以及联合使用两种或更多种延长QT间期的药物时,应更加意识到80岁及以上患者发生药物性TdP的风险。